Business Wire

Axway Named a Leader in New API Management Software Report

1.7.2024 19:42:00 EEST | Business Wire | Press release

Share

Axway (Euronext: AXW.PA), a leading provider of API management and integration software, is proud to announce that it has been positioned as a Leader in The Forrester Wave™: API Management Software, Q3 2024, published on July 1, 2024.¹

"We are always honored when our customers share the positive experiences and outcomes they have had with Axway," said Vince Padua, Chief Product Officer at Axway. "We're invested in their success, providing the expertise and guidance needed to treat APIs as strategic business products.”

Axway was one of 15 select companies that Forrester invited to participate in its evaluation, The Forrester Wave™: API Management Software, Q3 2024. In this evaluation of its Amplify API Management, Axway earned the highest scores possible in seven evaluation criteria, including federated gateway management, API product management, and adoption.

“This recognition validates for us our unique API business strategy program, which is just one example of how we go above and beyond to ensure you extract maximum value from API investments. We empower organizations with universal API management tools that break down barriers and provide a single source of truth for the entire API landscape,” said Padua.

The report notes: “Axway focuses on digital business that is multicloud, multiprotocol, and multigateway. Its roadmap seeks to deliver a more unified product line, non-REST protocol enhancements, more gateway federation, AI for API creation and consumption, and gateway modernization... It is the only vendor in this evaluation to provide robust support for third-party federated gateways...” ¹

“The Amplify platform lets you discover, use, and govern APIs across multiple gateways, vendors, and environments, simplifying adoption and use of APIs. But providing an industry-leading API management solution isn’t enough,” adds Padua. “Just as essential is accompanying our customers in designing an API management strategy that will drive the best results from a company’s investment.”

According to the report, “Reference customers say Axway is a supportive partner that listens to its customers. They also love its support for third-party gateways.” ¹

With Amplify API Management, the global manufacturing and engineering innovator Bosch was able to accelerate product and service innovation.

“We manage over 2,000 APIs using Amplify API Management, with a volume of several hundred million transactions per month. These APIs enable a wide range of use cases, from connecting SAP S/4HANA with other line-of-business solutions to supporting smart heating systems for office buildings,” said David Geiger, Head of API Management at Bosch Digital.

“And with Amplify Marketplace, developers can easily find the right APIs without traversing the entire organization; this saves a huge amount of time.”

Baird, an investment bank and financial services company, drove rapid adoption with a central API catalog and secure self-service consumption with Axway.

“Today, our developers can see all the APIs their peers have developed, identify any application dependences, and check the source repository to see who last worked on it,” said Jim Cornelius, SVP, IT Architect at Baird. “With a central view of which APIs are available, our teams can leverage already-existing code or even an entire API created by another team to accelerate their own development work. Without a doubt, this capability is reducing duplication of effort in our development process — helping us to minimize our time to market for new data-driven services.”

Click here to view a complimentary copy of The Forrester Wave™ report.

¹The Forrester Wave™: API Management Software, Q3 2024, Forrester Research, Inc., July 1, 2024

About Axway

Axway is an independent technology provider that sustainably grows enduring value for our customers based on a history of trust, security, and stability that goes back nearly 25 years. Our extensive portfolio, which encompasses Managed File Transfer, B2B Integration, Financial Accounting Hub, and comprehensive API management through Amplify, empowers organizations to seamlessly integrate their internal and external ecosystems and succeed in a shifting digital business landscape. Learn more at axway.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701226257/en/

Contacts

Media
Todd Holbrook
Tel. (480) 371-0113
tholbrook@axway.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye